Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies

Douglas H. Smith1, Peggy Winters-Digiaccinto1, Misrach Mitiku1, Sara O’Rourke2, Faruk Sinangil1,3, Terri Wrin4, David C. Montefiori5, Phillip W. Berman1,2*

1 VaxGen, Inc., Brisbane, California, United States of America, 2 Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, United States of America, 3 Global Solutions For Infectious Diseases, South San Francisco, California, United States of America, 4 Monogram Biosciences, South San Francisco, California, United States of America, 5 Duke University Medical School, Durham, North Carolina, United States of America

Abstract

Background: Previous clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization strategy involving priming with canarypox vCP1521 followed by boosting with rgp120 could provide significant, although modest, protection from HIV infection. Based on these results, there is renewed interest in the development of rgp120 based antigens for follow up vaccine trials, where this immunization approach can be applied to other cohorts at high risk for HIV infection. Of particular interest are cohorts in Africa, India, and China that are infected with clade C viruses.

Methodology/Principal Findings: A panel of 10 clade C rgp120 envelope proteins was expressed in 293 cells, purified by immunoaffinity chromatography, and used to immunize guinea pigs. The resulting sera were collected and analyzed in checkerboard experiments for rgp120 binding, V3 peptide binding, and CD4 blocking activity. Virus neutralization studies were carried out with two different assays and two different panels of clade C viruses. A high degree of cross reactivity against clade C and clade B viruses and viral proteins was observed. Most, but not all of the immunogens tested elicited antibodies that neutralized tier 1 clade B viruses, and some sera neutralized multiple clade C viruses. Immunization with rgp120 from the CN97001 strain of HIV appeared to elicit higher cross neutralizing antibody titers than the other antigens tested.

Conclusions/Significance: While all of the clade C antigens tested were immunogenic, some were more effective than others in eliciting virus neutralizing antibodies. Neutralization titers did not correlate with rgp120 binding, V3 peptide binding, or CD4 blocking activity. CN97001 rgp120 elicited the highest level of neutralizing antibodies, and should be considered for further HIV vaccine development studies.

Introduction

The development of a vaccine to prevent HIV infection is a global health priority. After more than 25 years of research, a modest level of protection was recently achieved in humans in a Phase 3 HIV-1 vaccine trial (RV144) involving more than 16,000 subjects in Thailand [1]. The RV144 study entailed priming immunizations with a recombinant canarypox vector (vCP1521) containing HIV env and gag genes to elicit cellular immune responses [2]. This was followed by booster immunizations with a bivalent rgp120 subunit vaccine, AIDSVAX B/E [3–5], to elicit antibody responses. The results of this trial were surprising because previous studies showed that these vaccines, given alone, were unable to elicit consistent T cell responses [6] or protective antibody responses [7,8]. Indeed, as a result of these studies, product development efforts on both rgp120-based vaccines and canarypox virus-based vaccines were largely discontinued, and efforts were refocused on adenovirus-based vaccines [9] and trimeric envelope glycoprotein vaccines [10,11]. However, the results from the RV144 trial have rekindled interest in both rgp120 subunit vaccines and canarypox virus vectors. There is now strong interest in confirmatory clinical studies with similar rgp120 vaccines and recombinant pox virus vectors designed for regions of the world where different clades (subtypes) of HIV are in circulation. Because it is desirable to match the genetic clade of vaccine immunogens to the viruses circulating in clinical cohorts, the AIDSVAX B/E rgp120 vaccine used in Thailand in the RV144 trial is considered inappropriate for clinical trials in Africa, India, or China, where clade C viruses account for the majority of new infections [UNAIDS, http://www.unaids.org]. As a consequence,
there is new interest in clade C rgp120 vaccines. These studies represent the only comparative immunogenicity of clade C rgp120s with diverse amino acid sequences, prepared in a manner identical to the envelope immunogens used in the AIDSVAX B/E vaccine. Here we compare the magnitude and specificity of functionally significant antibody responses to clade C rgp120 antigens. These results may be useful in the selection of clade C vaccine antigens that could potentially be used in clinical development studies designed to repeat the RV144 prime/boost immunization regimen.

Results

In considering the development of clade C vaccine immunogens, we wanted to encompass the range of sequence variation found in clade C envelope proteins from different regions of the world. For this purpose, we assembled a collection of ten clade C envelope genes with diverse sequences. The final collection included one isolate from Zambia, two each from China, India, and Tanzania, and three from South Africa (Table 1). An alignment of the amino acid sequences of these strains is provided in supplemental Figure S1. A pairwise comparison of protein sequence homology is provided in Table 2. A phylogenetic analysis of the HIV envelope protein rgp120 used in this study along with a diverse collection of clade C virus reference sequences from the panel of Li et al. [12] and the Los Alamos HIV sequence database (www.hiv.lanl.gov/.webloc) are provided in Figure S2. It can be seen that the viruses selected for protein expression studies are well distributed throughout the phylogeny and do not form unrepresentative clusters. However, the relevance of phylogenetic trees with respect to protective immune responses is uncertain. For this reason we were also interested in carrying out phylogenetic analysis of domains containing important neutralizing epitopes such as the V3 domain [13]. The results provided in Figure S3 and Table S1 show a high level of V3 sequence diversity within the panel of viruses studied.

All 10 envelope genes were then expressed in mammalian cells and purified for immunization studies. The mobility and purity of the purified envelope proteins by SDS-polyacrylamide gel chromatography is shown in Figure 1. The envelope proteins were found to be free of proteolysis products and greater than 98% pure as indicated by silver staining. Groups of 7 guinea pigs were immunized with each of the 10 clade antigens as described in the Materials and Methods section. In addition, two groups of animals were immunized with MN-rgp120 and A244-rgp120 that were included in the AIDSVAX B/E vaccine [3,4]. This vaccine was used in the Phase I/II and Phase III clinical trials alone [5,7] and in connection with vCP1521 in the RV144 clinical trial [1].

Initially, we measured the binding of the resulting antibodies to homologous and heterologous rgp120 by the same ELISA assay (supplemental Figure S4) described previously [14]. We found that all of the antibodies were immunogenic and elicited high levels of antibodies similar to those described previously [15]. We then examined the cross reactivity of each serum pool with rgp120s from clade C (ZM651), clade B (MN), clade E (CM244), and clade D (Z6) strains of HIV (Figure S4). Each of the clade C serum pools exhibited a high level of cross reactivity with envelope proteins from different clades; however, the magnitude of the immune response to the ZM651 protein was somewhat greater than that of the other immunogens. This level of cross reactivity was not unexpected, since previous studies also showed a high degree of cross reactivity of antisera to rgp120 with envelope proteins from CCR5 and CXCR4 viruses of different clades [3,16].

We next examined the formation of antibodies to the V3 domain, which is known to contain important neutralizing epitopes [17]. The sequence of the synthetic peptides used in these assays is provided in supplemental Table S1. Large differences were observed in the magnitude and specificity of the V3 antibody response elicited by different clade C immunogens (Figure 2). For example, antibodies to both the ZM651 and TZ97002 envelope proteins elicited a high level of cross reactivity with the V3 peptides from clade C and clade A peptides, but poor reactivity with the clade D V3 peptide. Many of the clade C pools reacted with the clade B V3 peptide and a few reacted with the clade E V3 peptide. Significantly, antisera to MN-rgp120 and A244-rgp120 exhibited poor cross reactivity with clade C V3 peptides, demonstrating that while antibodies to clade C immunogens are able to bind to clade B and E V3 peptides, the reverse is not true. These studies suggest that immunization with vaccines containing MN- and A244-rgp120 (e.g. AIDSVAX B/E) would not be effective in eliciting antibodies to the V3 domain of clade C viruses.

We next examined the ability of the clade C sera to inhibit the binding of rgp120 to soluble CD4 (Table 3). All of the envelopes tested elicited antibodies able to block the binding of rgp120 to CD4. As expected, the highest level of inhibition was usually, but not always, observed with homologous protein. However, there appeared to be significant differences in the ability of different immunogens to elicit CD4 blocking antibodies. For example, the ZM651, IN98025, and IN98026 sera were less effective in inhibiting the binding of heterologous envelopes to CD4 than sera to most of the other antigens tested.

The ability of antisera from all 10 clade C antigens to neutralize clade B and C viruses was measured in two different laboratories using two different panels of viruses (Tables 4 and 5). In the first assay (Table 4), pseudotype viruses were prepared from a panel of 10 heterologous clade C viruses and 4 clade B viruses, and used to infect U87 cells transfected with CD4 and chemokine receptors (U87 pseudotype assay)[18,19]. Interestingly, 8 of the 10 clade C sera pools showed significant neutralization against laboratory-adapted clade B viruses (e.g., MN and SF162), whereas the prototypic clinical isolate, JRCSF, was resistant to neutralization. This result confirmed the high level of cross reactivity of clade C antisera against clade B viral proteins. When the neutralizing activity against clade C clinical isolates was examined, significant differences were seen among the sera elicited by different antigens.

### Table 1. Listing of clade C viruses.

| Strain      | Year collected | Origin |
|-------------|----------------|-------|
| CN97001     | 1997           | China |
| CN98005     | 1998           | China |
| IN98025     | 1998           | India |
| IN98026     | 1998           | India |
| TZ97005     | 1997           | Tanzania |
| TZ97008     | 1997           | Tanzania |
| ZA97002     | 1997           | South Africa |
| ZA97010     | 1997           | South Africa |
| ZA97012     | 1997           | South Africa |
| ZM651       | 1996           | Zambia |

Clade C envelope genes were cloned from HIV infected cell lysates provided by the Joint United Nations program on HIV/AIDS and the National Institutes of Allergy and Infectious Diseases, NIH. Viruses were selected on the basis of geographical diversity as well as variation in V3 domain sequences. doi:10.1371/journal.pone.0012076.t001
For example, the sera to the ZM651, IN98025, and ZA97012 envelopes showed the weakest neutralization titers and were unable to neutralize any of the clade C viruses in the panel. In contrast, the sera raised against the CN97001 and IN98026 envelope proteins neutralized multiple clade C viruses. While the neutralization titers to these clade C envelopes were low, so were the neutralization titers obtained with the positive control serum, N16, from an HIV infected individual. This serum is known to possess high levels of broadly neutralizing antibodies [20]. Thus the viruses in this panel for the most part represented difficult to neutralize viruses. The inclusion of the aMLV virus in the U87 pseudotype assay provided a reliable control, demonstrating that the neutralization activity observed was not an artifact of a non-specific immune response to viral membranes.

The same sera were then tested in a second assay (TZM-bl assay) that included 6 clade C viruses and 2 clade B viruses. The results obtained in this TZM-bl assay (Table 5) were qualitatively similar to results obtained in the U87 pseudotype neutralization assay described above. We observed that most of the clade C sera were able to neutralize the clade B, laboratory adapted isolates, MN and SF162. Both assays showed that the CN97001 and IN98026 sera possessed the highest levels of neutralizing activity, whereas the ZM651, IN98025 and ZA97012 sera exhibited the lowest level of neutralizing activity.

**Discussion**

These studies demonstrated that envelope proteins from clade C virus were all comparably immunogenic as measured by rgp120 binding; however, some were better than others in eliciting antibodies able to bind to the V3 domain, or block the binding of CD4 to rgp120. Most of the sera to clade C viruses were able to neutralize tier 1 strains of clade B viruses, thus demonstrating some level of cross clade neutralizing activity. This activity may well be attributable to antibodies to the V3 domain of clade C antigens which exhibited significant cross reactivity with clade B V3 domain peptides. It is well known that antibodies to the V3 domain are particularly effective in neutralizing tier 1 viruses. As has been described previously, there was poor neutralization of clinical isolates of HIV-1. This continues to be a problem with all of the candidate HIV vaccines tested to date [21,22]. Although it has long been speculated that that trimeric forms of HV envelope proteins would be better than monomeric rgp120 with respect to eliciting antibodies able to neutralize clinical isolates, the results to date have been equivocal [23].

Overall the antibody responses strains such as CN97001, and IN98026 were similar to those seen with the envelope proteins contained in the AIDSVAX B/E vaccine used in the RV144 clinical trial. However, other strains (e.g. ZM651, IN98025, ZA97010, ZA97012) were significantly less effective in eliciting neutralizing antibodies. We did not observe any significant correlation between antibodies able to neutralize primary isolates and any of the antibody binding assays. Multiple sera that possessed significant CD4 blocking titers failed to exhibit virus neutralization; demonstrating that CD4 blocking antibodies to rgp120 are not a correlate of virus neutralization. Thus, CD4 blocking antibodies elicited against gp120 immunogens appear to differ from CD4 blocking antibodies present in sera from HIV-infected individuals, where immunoadsorption studies have shown that a significant proportion of broadly neutralizing antibodies possess CD4 blocking activity [24,25]. Whether this difference can be attributed to differences in antibody avidity or antibody
specificity remains to be determined. Based on the main criteria used to select the immunogens included in the AIDSVAX B/E vaccine used in the RV144 trial (e.g. immunogenicity, neutralizing activity, and common sequence polymorphisms at neutralizing sites), rgp120 from the CN97001 strain of HIV-1, would be our recommendation for a clade C immunogen to include in a subunit boost in studies designed repeat the RV144 immunization regimen. However, we don’t know if in vitro neutralization is a correlate of protective immunity in humans. It is possible that antibodies with activities distinct from those measured in these studies, might be

Table 3. Blocking of CD4 binding to rgp120 by antisera against subtype C rgp120.

| Antiserum | Coat | ZM651 | IN98025 | IN98026 | TZ97008 | ZA97002 | TZ97005 | CN98005 | ZA97010 | CN97001 | ZA97012 |
|-----------|------|-------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| ZM651     | 67   | 39    | 55      | 71      | 76      | 83      | 67      | 77      | 77      | 54      |
| IN98026   | 46   | 50    | 80      | 69      | 70      | 77      | 69      | 73      | 74      | 61      |
| TZ97008   | 26   | 14    | 35      | 69      | 60      | 61      | 53      | 66      | 62      | 52      |
| ZA97002   | 64   | 63    | 83      | 83      | 84      | 77      | 66      | 79      | 75      | 70      |
| TZ97005   | 47   | 27    | 46      | 56      | 62      | 77      | 50      | 56      | 57      | 51      |
| CN98005   | 47   | 39    | 55      | 59      | 64      | 68      | 76      | 68      | 70      | 57      |
| ZA97010   | 32   | 30    | 48      | 72      | 72      | 64      | 58      | 91      | 70      | 62      |
| CN97001   | 41   | 30    | 45      | 64      | 71      | 74      | 64      | 80      | 96      | 62      |
| ZA97012   | 47   | 37    | 53      | 75      | 73      | 69      | 64      | 75      | 71      | 76      |

The ability of antibodies to inhibit the binding of CD4-IgG to rgp120 was measured using an assay similar to that described previously [14]. Briefly, rgp120 was captured onto microtiter dishes. Sera were added at a 1:200 dilution in duplicate and incubated 2 hr, and soluble CD4 was then added without washing. The amount of bound CD4 with and without added anti-rgp120 sera was monitored by the binding of HRP-labeled mouse monoclonal antibody to CD4. Results using rgp120 from the IN98025 isolate were not available due to the inability of this envelope protein to bind CD4-IgG.

doi:10.1371/journal.pone.0012076.t003
Table 4. Neutralization of clade C and clade B viruses in the U87 pseudotype neutralization assay by antibodies to rgp120.

| Antiserum | Virus | Clade | ZM651 | IN98025 | IN98026 | TN97008 | TA97002 | TZ79005 | CN98005 | TA97010 | CN97001 | TA97012 | N16 |
|-----------|-------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-----|
| 21068 | C | - | - | 27 | 12 | 21 | 13 | - | - | 50 | - | 150 |
| 92ZV101 | C | - | - | 24 | - | - | 12 | - | - | 66 | - | 233 |
| 93IN101 | C | - | - | 18 | - | - | 12 | - | - | - | - | 37 |
| 93IN999 | C | - | - | - | - | - | - | - | - | - | - | 72 |
| 93MV960 | C | - | - | 33 | 20 | 21 | - | 44 | - | 79 | - | 270 |
| 97ZV101 | C | - | - | - | - | - | - | - | - | - | - | 45 |
| 98BR004 | C | - | - | - | - | - | - | - | - | - | - | 100 |
| 98CN006 | C | - | - | 18 | - | 14 | 14 | - | - | 42 | - | 116 |
| 98CN009 | C | - | - | 19 | - | - | - | - | - | - | - | 60 |
| 98IN022 | C | - | - | 95 | 55 | 61 | 17 | 261 | - | 345 | 38 | 73 |
| 8AL | B | - | - | 33 | 52 | 13 | - | 68 | - | 430 | - | 683 |
| JRC5F | B | - | - | - | - | - | - | - | - | - | - | 211 |
| MN | B | - | - | 1882 | 1669 | 355 | 202 | 2324 | 796 | 8863 | 36 | 3798 |
| NL43 | B | - | - | 84 | 161 | 282 | 159 | 69 | 66 | 170 | 79 | 1510 |
| SF162 | B | 183 | - | 3457 | 6669 | 579 | 1875 | 4403 | 3044 | 13437 | 197 | 7358 |
| aMLV | B | <10 | 11 | <10 | <10 | <10 | <10 | 14 | 20 | <10 | <10 | <10 |

Virus neutralization titers were measured in the U87 pseudotype virus neutralization assay [18,19]. Virus designations include the country of origin as follows: BR, Brazil; CN, China; IN, India; MW, Malawi; SA, South Africa; ZA, South Africa; ZM, Zambia; ZW, Zimbabwe. ND, indicates not done. The neutralizing antibody titer (IC50) is defined as the reciprocal of the plasma dilution that produces a 50% inhibition in target cell infection. A dash indicates no significant neutralization. For this assay, virus neutralization was considered significant if the neutralization titers were at least 3-fold greater than those observed against the control pseudotype virus, aMLV. The positive control was an HIV+ sera (N16). doi:10.1371/journal.pone.0012076.t004

Table 5. Neutralization of clade C and B viruses in the TZM-bl neutralization assay by antibodies to rgp120.

| Antiserum | Virus | Clade | ZM651 | IN98025 | IN98026 | TN97008 | TA97002 | TZ79005 | CN98005 | TA97010 | CN97001 | TA97012 | NGPS | 4E10 |
|-----------|-------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|------|------|
| SA123.6 | C | - | - | - | - | - | - | 62 | 87 | - | 103 | - | <20 | 0.2 |
| SA151.2 | C | - | - | - | - | - | - | - | - | - | - | - | <20 | 0.4 |
| SA156.12 | C | - | 83 | 77 | - | - | - | - | - | - | - | - | <20 | 0.43 |
| SA172.17 | C | 69 | 64 | 146 | 88 | 86 | 117 | - | - | 160 | - | 24 | 0.03 |
| ZM233MP.B6 | C | - | - | 98 | - | - | - | - | - | 133 | - | 22 | 0.61 |
| ZM197MP.B7 | C | - | - | - | - | - | - | - | - | - | - | - | <20 | 0.1 |
| MN | B | - | - | 2958 | 2935 | 626 | - | 2120 | 1357 | 38225 | - | <20 | 0.04 |
| SF162LS | B | 319 | - | 3536 | 6714 | 517 | 1351 | 2671 | 3320 | 12705 | 89 | <20 | 0.4 |

Virus neutralization titers were measured by the TZM-bl neutralization assay [28]. Virus designations include the country of origin as follows: BR, Brazil; CN, China; IN, India; MW, Malawi; SA, South Africa; ZA, South Africa; ZM, Zambia; ZW, Zimbabwe. ND, indicates not done. The neutralizing antibody titer (IC50) is defined as the reciprocal of the plasma dilution that produces a 50% inhibition in target cell infection. A dash indicates no significant neutralization. For this assay, neutralization titers were considered significant if they were 3-fold greater than the titers obtained for each virus pseudotype with normal guinea pig serum (NGPS). The positive control was the 4E10 broadly neutralizing monoclonal antibody. doi:10.1371/journal.pone.0012076.t005
Materials and Methods

Production of antigens

A collection of ten clade C envelope genes with diverse sequences was assembled for this study. Nine of these were PCR amplified from infected cell lysates provided by Dr. S. Osmanov (WHO-UNAIDS, Geneva, Switzerland) and one (ZM651) was provided by Dr. F. Gao (Duke University, Durham, NC). In order to produce antigens homologous to those used in the RV144 vaccine trial, codon optimized rgp120 sequences were expressed as fusion proteins where the signal sequence and 12 amino acids from the mature N-terminus of rgp120 were deleted, and replaced with the signal sequence and 27 N-terminal amino acids of the mature form of herpes simplex virus type 1 glycoprotein D (gD-1) as described previously [26]. The resulting constructs were cloned into a pCI based expression vector (Promega Corp, Madison, WI) and expressed in Lipofectamine Plus (Invitrogen, Carlsbad, CA) transfected 293 cells. Recombinant envelope proteins were purified from growth conditioned cell culture media and subjected to immunoadfinity chromatography, using a monoclonal antibody specific for the HSV-1 flag epitope.

Guinea pig immunizations

Immunization studies (approval number 10245) were carried out at Covance Research Products (Denver, PA), an AAALAC accredited organization (OLAW assurance number: A3350-01; USDA research registration number: 29-R-007). The study was reviewed and approved by the CRP’s Institutional Animal Care and Use Committee (IACUC). Each purified protein was then used to immunize groups of 6 guinea pigs. Each animal received 10μg of rgp120 on Days 0, 14, and 42. All antigens were formulated in QS21 adjuvant that had previously demonstrated a substantial dose-sparing ability as well as eliciting a strong antibody response. OD490 for a single dilution is shown. The data bars indicated were incubated at a single dilution (1:5000), allowed to bind, then detected using an HRP-labeled anti-guinea pig IgG antibody. OD490 for a single dilution is shown. The data bars indicated were incubated at a single dilution (1:5000), allowed to bind, then detected using an HRP-labeled anti-guinea pig IgG antibody.

Antibody binding assays

Antibody binding to rgp120 from homologous and heterologous rgp120 by ELISA as described previously [5,7,14]. Antibody binding assays were carried out with pooled sera from the 7 animals in each group immunized with rgp120 from different strains of HIV. Antibody binding to synthetic peptides from the V3 domains of 10 subtype C gp120 genes was measured in two different assays that made use of pseudotype viruses. The first assay (U87 pseudotype assay) was performed by Monogram Biosciences (S. San Francisco, CA) and utilized a panel of 10 heterologous clade C viruses and 4 clade B viruses. In this assay, pseudotype viruses prepared in 293 cells were used to infect U87 cells transfected with CD4 and either the CCR5 or CXCR4 chemokine receptors [18,19]. The second assay (TZM-bl assay) was carried out by Dr. D. Montefiori (Duke Medical School) and utilized the TZM-bl assay format [12,28]. This assay included 6 clade C viruses and 2 clade B viruses.

Virus neutralization assays

The ability of antibodies to rgp120 to neutralize various strains of HIV was measured in two different assays that made use of pseudotype viruses. The first assay (U87 pseudotype assay) was performed by Monogram Biosciences (S. San Francisco, CA) and utilized a panel of 10 heterologous clade C viruses and 4 clade B viruses. In this assay, pseudotype viruses prepared in 293 cells were used to infect U87 cells transfected with CD4 and either the CCR5 or CXCR4 chemokine receptors [18,19]. The second assay (TZM-bl assay) was carried out by Dr. D. Montefiori (Duke Medical School) and utilized the TZM-bl assay format [12,28]. This assay included 6 clade C viruses and 2 clade B viruses.

Clade C gp120 Immunogenicity

Phylogenetic analysis

Phylogenetic trees were constructed in EMBoss http://www.ebi.ac.uk using the neighbor joining method [29] by percentage identity, on sequences pre-aligned using the MAFFT algorithm [30].

Supporting Information

Figure S1 Alignment of subtype C gp120 amino acid sequences. Amino acid sequences were deduced from the DNA sequences of the 10 subtype C gp120 genes. The sequences were aligned using the MacVector Sequence Analysis package (Accelrys Inc. San Diego, CA). The alignment was then edited manually to align significant features, e.g. a pair of conserved N-linked glycosylation sites in the V1 hypervariable region. Bases that match the consensus of the aligned sequences are boxed. The sequence of HXB2 was included as a reference. 

Figure S2 Phylogenetic analysis of gp120. Phylogenetic relationships between the 10 subtype C gp120 genes selected for expression studies and 12 clade C genes from standard reference panels. Ten clade C genes were obtained from the UNAIDS and NIAID Networks for HIV Isolation and characterization. These included: ZA97002.7-7, ZA9710, ZA9712, CN97001, CN98005, IN98025, IN98026, TZ97005, TZ97009, ZM651. These were compared to 12 envelope genes from the subtype C reference sequences from the Los Alamos sequence database www.hiv.lanl.gov/. The tree was constructed in EMBoss http://www.ebi.ac.uk using the neighbor joining method [29] by percentage identity, on sequences pre-aligned using the MAFFT algorithm [30]. Horizontal lengths are proportional to distance, vertical distances are for clarity only. 

Figure S3 V3 Phylogenetic Tree. Phylogenetic relationships between the the V3 domains of 10 subtype C gp120 genes selected for expression studies and the V3 domains of 12 clade C genes from standard reference panels. Ten clade C genes were obtained from the UNAIDS and NIAID Networks for HIV Isolation and characterization. These included: ZA97002.7-7, ZA9710, ZA9712, CN97001, CN98005, IN98025, IN98026, TZ97005, TZ97009, ZM651. These were compared to 12 envelope genes from the subtype C reference sequences from the Los Alamos sequence database www.hiv.lanl.gov/. The tree was constructed in EMBoss http://www.ebi.ac.uk using the neighbor joining method [29] by percentage identity, on sequences pre-aligned using the MAFFT algorithm [30]. Horizontal lengths are proportional to distance, vertical distances are for clarity only. 

Figure S4 Binding of antisera against subtype C gp120s to envelope proteins from clade C, B, E, and D viruses. ELISA plates were coated with the gp120 from subtype C (ZM651), B (MN), E (A244) or D (Z6). Pooled antisera raised against subtype C gp120s indicated were incubated at a single dilution (1:5000), allowed to bind, then detected using an HRP-labeled anti-guinea pig antibody. OD490 for a single dilution is shown. The data bars are color coded and correspond to the following strains: ZM1, ZM651; IN1, IN98025; IN2, IN98026; TZ2, TZ97008; ZA1,
| References |
|----------------|
| **1.** Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–20. |
| **2.** Tartaglia J, Ezler JL, El Habib R, Limbach K, Meignier B, et al. (1998) Canaropyx virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retrovirology 14 Suppl 3: S291–8. |
| **3.** Berman PW (1998) Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 14 Suppl 3: S277–89. |
| **4.** Berman PW, Huang W, Riddle I, Gray AM, Wein T, et al. (1999) Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 265: 1–9. |
| **5.** Pisetskyy P, Berman PW, Phounirut S, Sutharaksam P, Rakshit S, et al. (2004) Phase II/I study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 37: 1160–5. |
| **6.** Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, et al. (2007) Phase 2 study of an HIV-1 canaropyx vaccine (cGPl452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 44: 203–12. |
| **7.** Pisetskyy P, Gilbert P, Guwih M, Hayward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661–71. |
| **8.** Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654–65. |
| **9.** Bachrach SP, Melnitra DV, Auer A, Fiagbedor DW, Morg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1081–93. |
| **10.** Nikouli JA, Perl H, Settembr E, Freeman M, Grandper L, et al. (2010-00006) Breadth of neutralizing antibodies elicited by stable, homogenous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 84: 3275–89. |
| **11.** Sanders RW, Vesem A, Schaeke L, Master A, Schiller L, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8375–90. |
| **12.** Li M, Salazar-Gonzalez JF, Derley CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 1176–90. |
| **13.** Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739–69. |
| **14.** Gilbert PB, Peterson ML, Follmann D, Houglens MG, Francis DP, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666–77. |
| **15.** Powell MF, Eastman D, Lim A, Lucas C, Peterson ML, et al. (1995) Effect of adjuvants in immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res Hum Retroviruses 11: 203–9. |
| **16.** Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, et al. (1994) Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 8: 591–601. |
| **17.** Pantophlet R, Wein T, Cavacini LA, Robinson JE, Burton DR (2008) Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 361: 251–60. |
| **18.** Richman DD, Wein T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144–9. |
| **19.** Schweighardt B, Liu Y, Huang W, Chappee C, Lee YS, et al. (2007) Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 46: 1–11. |
| **20.** Dhillon AK, Donners H, Pantophlet R, Johnson WE, Deckert JM, et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548–62. |
| **21.** Johnston MI, Fasihi AS (2007) An HIV vaccine—evolving concepts. N Engl J Med 356: 2073–81. |
| **22.** Karlsson Hestdahl GB, Fouchier RA, Phogat S, Burton DR, Sedsloski J, et al. (2000) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143–53. |
| **23.** Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomer gp120. Virology 366: 245–62. |
| **24.** Binley JM, Lybarger E, Crooks ET, Seaman MS, Gray E, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasma from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82: 11651–68. |
| **25.** Li Y, Migueles SA, Welcher B, Schalk LA, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032–4. |
| **26.** Lasky LA, Groopman JE, Fennie CW, Benza PM, Capon DJ, et al. (1986) Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233: 209–12. |
| **27.** Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, et al. (2005) HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 192: 974–83. |
| **28.** Montefiori D (2004) Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current Protocols in Immunology. 12.11.1–12.11.15. |
| **29.** Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406–25. |
| **30.** Katoh K, Kuma K, Toh H, Miyata T (2005) MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res 33: 511–8. |

**Table 1** Sequence of V3 peptides used in ELISA. The sequence of V3 peptides from the MN (clade B) and A244 (clade E) strains of HIV are indicated, along with the sequences of peptides synthesized based on consensus sequences from clade A, C and D envelope proteins. The clade C consensus sequence matched that of the ZM651, CN97001, CN97005, and IN98026 strains of HIV. The IN1, TZ1, ZA1/Z2, and ZA3 peptides matched the sequences of the IN98025, TZ97005, ZA97002, and ZA97012 envelopes, respectively. The consensus clade A V3 peptide matched that found in the TZ97008 isolate. Found at: doi:10.1371/journal.pone.0012076.s004 (0.08 MB PDF)